India defers decision on drug pricing policy

8 November 2012

The Indian Cabinet yesterday deferred the decision on the draft pharmaceutical pricing policy that aims to increase the number of essential medicines under price control from 74 to 348, according India’ Economic Times and other local media reports.

"The decision on the pharma policy has been deferred," Finance Minister P Chidambaram told reporters after the Cabinet meeting.

Under the draft pharmaceutical pricing policy approved by the group of ministers, headed by Agriculture Minister Sharad Pawar, prices of 348 essential medicines will be controlled. That apart, the draft policy aims at fixing prices based on weighted average of prices of all brands, which have more than 1% market share.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >